Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LibiGel for Hypoactive Sexual Desire Disorder
NCT00612742Phase 3Completed
- Sponsor
- BioSante Pharmaceuticals
- Start
- Jan 2008
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD), sponsored by BioSante Pharmaceuticals. Started Jan 2008; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00612742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612742.